Japan Tissue Engineering Co., Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2022
July 27, 2022 at 11:30 am IST
Share
Japan Tissue Engineering Co., Ltd. reported earnings results for the first quarter ended June 30, 2022. For the first quarter, the company reported sales was JPY 422.72 million compared to JPY 478.34 million a year ago. Net loss was JPY 268.21 million compared to JPY 129.48 million a year ago. Basic loss per share from continuing operations was JPY 6.6 compared to JPY 3.19 a year ago.
Japan Tissue Engineering Co Ltd is a Japan-based company mainly engaged in regenerative medicine product business, regenerative medicine outsourcing business, and research and development support business. The Company operates through three segments. The Regenerative Medicine Product segment develops regenerative medicine products using tissue engineering, and manufactures and sells the products for medical institutions. The regenerative medicine products include autologous cultured epidermis JACE, and autologous cultured cartilage JACK. The Regenerative Medicine Outsourcing segment provides contract development and manufacturing organization (CDMO) services, contract research organization (CRO) services, consulting services, and contract manufacturing services for specific cell processed products. The Research and Development Support segment manufactures and sells human cultured tissues that apply advanced culture technology accumulated through the development of in-house products.